Endoscopic ultrasound-guided transbronchial or transoesophageal lymph node aspiration is increasingly used as a method of diagnosing nonsmall cell carcinoma. Data validating the accuracy of cell typing of nonsmall cell carcinoma using these cytological samples has not been assessed.23 samples were identified in Edinburgh, UK and a further 25 in Cambridge, UK, with matching histological samples. The morphological cell type, as assessed on the cytological preparations and cell blocks, was recorded and immunohistochemical staining was performed, where possible, as an adjunct. The final cell type, as assessed by morphology with or without immunohistochemistry, was correlated with that reported in the paired histological samples.Cell blocks with tumour were available in 39 out of 48 cases. The accuracy of cell typing when no cell block was available was four out of nine cases. This increased to 25 out of 39 when a cell block was available, increasing to 33 out of 39 with the addition of immunohistochemistry. The overall accuracy of classification was 37 out of 48 cases.Accurate cell typing of nonsmall cell carcinomas can be performed using endoscopically derived fine-needle aspirates. The importance of obtaining sufficient material for the production of cell blocks is critical in allowing optimal assessment. KEYWORDS: Classification, cytology, fine-needle aspiration, immunohistochemistry, nonsmall cell lung carcinoma E ndobronchial ultrasound (EBUS)-or endoscopic ultrasound (EUS)-guided fine-needle aspiration (FNA) has been used as a minimally invasive method of sampling mediastinal and hilar lymph nodes as part of the staging process in patients with lung carcinoma [1][2][3][4]. Studies from various centres have demonstrated such techniques to have a high degree of accuracy and diagnostic yield in identifying node involvement by metastatic carcinoma [1][2][3][4]. This has led to increasing popularity over the last few years and the role of EBUS/EUS-FNA has evolved; it is now perceived as being a method of allowing simultaneous diagnosis and staging of lung cancer in one procedure [4].Developments in oncological therapeutics have simultaneously led to the concept of individualised therapy for nonsmall cell lung cancers (NSCLCs) and the recent introduction of new drugs licensed for tumours with nonsquamous histology [5]. This has led to expectations on pathologists to robustly identify squamous and glandular differentiation in small biopsy and cytological samples, when previously the term ''NSCLC, not otherwise specified (NSCLC-NOS)'' would have been sufficient to allow patient management [6].Accurate cell typing of nonsmall cell carcinomas in small diagnostic biopsy specimens has been recognised for many years to present a significant problem to pathologists, given the focal nature of specific diagnostic features and their frequent absence in small diagnostic specimens [7][8][9]. Similar issues exist when assessing cytological specimens, with the added complication that the architectural features that indic...